JOHN M. LEONARD - 11 Dec 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
President and CEO, Director
Signature
/s/ James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
11 Dec 2025
Net transactions value
-$436,720
Form type
4
Filing time
12 Dec 2025, 16:09:29 UTC
Previous filing
25 Apr 2025
Next filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LEONARD JOHN M President and CEO, Director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE /s/ James Basta, attorney-in-fact 12 Dec 2025 0001563584

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise $341,220 +49,959 +4.6% $6.83 1,127,074 11 Dec 2025 Direct
transaction NTLA Common Stock Sale $474,111 -49,959 -4.4% $9.49 1,077,115 11 Dec 2025 Direct F1, F2
transaction NTLA Common Stock Sale $310,919 -32,832 -3% $9.47 1,044,283 11 Dec 2025 Direct F1, F3
transaction NTLA Common Stock Sale $51,354 -5,355 -0.51% $9.59 1,038,928 11 Dec 2025 Direct F1, F4
transaction NTLA Common Stock Options Exercise $58,444 +8,557 +0.82% $6.83 1,047,485 12 Dec 2025 Direct
holding NTLA Common Stock 58,415 11 Dec 2025 By Trust F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Options Exercise $0 -49,959 -85% $0.000000 8,557 11 Dec 2025 Common Stock 49,959 $6.83 Direct F6
transaction NTLA Stock Option (right to buy) Options Exercise $0 -8,557 -100% $0.000000 0 12 Dec 2025 Common Stock 8,557 $6.83 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
F5 Shares held by the John M. Leonard 2015 Irrevocable Trust.
F6 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025.